Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation. 1988

K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.

The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10-100 micrograms improved the cardiac function curve and restored it to the control level at 100 micrograms. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective beta 1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D010424 Pentobarbital A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) Mebubarbital,Mebumal,Diabutal,Etaminal,Ethaminal,Nembutal,Pentobarbital Sodium,Pentobarbital, Monosodium Salt,Pentobarbitone,Sagatal,Monosodium Salt Pentobarbital
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure

Related Publications

K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
January 1991, European journal of pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
February 1987, European journal of pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
December 1987, Journal of cardiovascular pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
March 1989, Japanese journal of pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
April 1992, Japanese journal of pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
January 1990, European journal of pharmacology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
May 1983, Japanese heart journal,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
June 1992, The Journal of pharmacology and experimental therapeutics,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
March 1997, Journal of the American College of Cardiology,
K Satoh, and K Nunoki, and T Goto, and M Hosono, and H Hashimoto, and Y Sato, and N Taira
November 1987, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!